Table A1.

Association Between Folate, Vitamin B12, and Homocysteine and Prevalent Cognitive Impairment at Baseline and Incident Cognitive Impairment After 5 Years (SMMSE≤25) in the Newcastle 85+ Study

	Prevalent Cognitive Impairment				Incident Cognitive Impairment
	Model 1		Model 2		Model 1		Model 2
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
RBC folate, nmol/L
Q2 (612–870)	0.77 (0.44–1.33)	.35	0.73 (0.40–1.31)	.29	1.68 (0.68–4.14)	.26	1.68 (0.61–4.65)	.31
Q3 (870–1280)	0.74 (0.43–1.28)	.29	0.71 (0.38–1.30)	.26	2.40 (1.02–5.65)	.05	2.59 (0.96–7.02)	.06
Q4 (>1280)	0.84 (0.49–1.45)	.53	0.73 (0.40–1.34)	.31	1.10 (0.42–2.87)	.84	0.84 (0.27–2.67)	.88
Plasma vitamin B12, pmol/L
Q2 (170–232)	0.80 (0.46–1.40)	.44	0.64 (0.35–1.18)	.16	1.15 (0.52–2.53)	.73	1.41 (0.56–3.53)	.46
Q3 (232–325)	1.06 (0.62–1.81)	.84	1.03 (0.57–1.87)	.93	0.64 (0.26–1.54)	.32	0.61 (0.23–1.66)	.34
Q4 (>325)	0.89 (0.51–1.54)	.66	0.67 (0.36–1.23)	.19	0.85 (0.36–2.03)	.72	1.12 (0.40–4.11)	.84
Total homocysteine, μmol/L
Q2 (13.5–16.7)	0.99 (0.56–1.75)	.96	1.05 (0.57–1.96)	.87	1.12 (0.50–2.54)	.79	1.71 (0.68–4.30)	.26
Q3 (16.7–21.4)	1.18 (0.67–2.09)	.57	1.40 (0.75–2.60)	.29	0.79 (0.34–1.88)	.60	0.97 (0.37–2.56)	.96
Q4 (>21.4)	1.55 (0.89–2.69)	.13	2.15 (1.12–4.11)	.02	1.10 (0.46–2.64)	.83	1.81 (0.63–5.25)	.27

Quartile 1 (<612 nmol/L RBC folate, <170 pmol/L plasma vitamin B12, and <13.5 tHcy, respectively) was used as the reference category (1.00) for all models. Model 1 is unadjusted, Model 2 is adjusted for alcohol intake, smoking status, APOE genotype (rs429358 and rs7412), sex, education, BMI, depression, hypertension, diabetes type 1 and 2, history of cardiovascular diseases, and physical activity. RBC folate and plasma vitamin B12 models were additionally adjusted for tHcy and the homocysteine model for renal impairment.